Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and quality of life within 3 months for people with heart failure due to either reduced or preserved cardiac function, even if they didn’t also have type 2 diabetes, according to the late-breaking CHIEF-HF study presented at the American Heart Association’s Scientific Sessions 2021. Type 2 Diabetes Canagliflozin 100mg Tablet.

News | Heart Failure

Heart Failure Symptoms Improved With a Type 2 Diabetes Medicine in Fully Remote Trial

November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...

November 17, 2021

News | Structural Heart

Surgery to Replace Heart Valve Beneficial Even With No Symptoms of Severe Aortic Stenosis

November 17, 2021 — For people experiencing severe aortic stenosis who do not have symptoms or need symptom relief ...

November 17, 2021

Videos | Cardiogenic Shock

VIDEO: Updates Made to the SCAI Cardiogenic Shock Classifications

Srihari Naidu, M.D., FACC, FAHA, FSCAI, is the director of both the cardiac cath labs and Hypertrophic Cardiomyopathy ...

November 16, 2021

News | Hypertension

Pacemaker for Hypertension Shows Significant Clinical Impact

November 12, 2021 — Orchestra BioMed Inc. announced multiple presentations of long-term clinical results and ISH ...

November 12, 2021

President Joe Biden today announced his intention to nominate cardiologist Robert Califf, M.D., MACC, for the position of commissioner of food and drugs to lead the U.S. Food and Drug Administration (FDA).

Feature | Cardiovascular Business | By Dave Fornell, DAIC Editor

President Biden Nominates Cardiologist Robert Califf for FDA Commissioner

November 12, 2021 — President Joe Biden today announced his intention to nominate cardiologist Robert Califf, M.D., MACC ...

November 12, 2021

Medtronic Apollo Intrepid TMVR is currently in the middle of a U.S. clinical trial. #TCT #TCT21 #TMVR

News | Structural Heart

Medtronic Intrepid Transcatheter Mitral Valve Successfully Uses Transfemoral Delivery

November 10, 2021 — Medtronic presented early data for its self-expanding Intrepid transcatheter mitral valve ...

November 10, 2021

News | Cardiovascular Business

Medicare Increases Hospital Outpatient Payment for Peripheral Intravascular Lithotripsy

November 10, 2021 — Shockwave Medical, a developer of Intravascular Lithotripsy (IVL) to treat complex calcified ...

November 10, 2021

News | Heart Failure

Ancora Heart AccuCinch System Shows Positive 12 Month Outcomes in Multi-study Analysis

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

November 10, 2021

TCT 2021 Announces Late-Breaking Clinical Trials

Feature | TCT

Links to all the TCT 2021 Late-Breaking Clinical Trials

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 Transcat ...

November 10, 2021

The Teleflex Manta large bore vascular closure device #TCT2021

News | Vascular Closure Devices

Plug-based Vascular Closure Following TAVR Offers Shorter Hemostasis Time Than Suture-based Devices

November 9, 2021 — Results from the largest randomized trial available comparing different closure device strategies ...

November 09, 2021

An illustration of the Recor renal denervation ablation balloon at work in the renal artery.. Renal Denervation Recor RDN ablation balloon #TCT2021

News | Hypertension

Renal Denervation Combined With Medication Can Treat Resistant Hypertension

November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...

November 09, 2021

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

News | Heart Valve Technology

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

November 09, 2021

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021